Olema Pharmaceuticals, Inc.OLMANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank29
3Y CAGR-24.1%
5Y CAGR-36.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-24.1%/yr
Annual compound
5Y CAGR
-36.1%/yr
Recent acceleration
Percentile
P29
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 26.65% |
| 2024 | 44.55% |
| 2023 | 4.70% |
| 2022 | 61.01% |
| 2021 | 272.88% |
| 2020 | 249.59% |
| 2019 | 131.54% |
| 2018 | 0.00% |